Invuity to be Acquired by Stryker, Share Price Increases

- September 11th, 2018

Invuity announced on Tuesday that it will be acquired by Stryker for US$7.40 per share, which comes to US$190 million.

While certain medical device companies focus on building the best technology for surgical robotics, when the opportunity to acquire a new company becomes available, new possibilities for shareholders also come into play.

In an all cash deal, Invuity (NASDAQ:IVTY) announced on Tuesday (September 11) it will be acquired by Stryker (NYSE:SYK) for US$7.40 per share, equalling out to US$190 million.

Invuity’s share price increased 27.35 percent from its previous close of US$5.75 on Monday (September 1o) to US$7.35. In short, this means the acquisition — which is expected to close in Q4 2018 — will be profitable for shareholders.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

“The combination of Stryker’s established leadership in minimal access surgery paired with Invuity’s suite of enabling visualization and surgical devices should facilitate better patient outcomes and operating room efficiencies in women’s health, general surgery, electrophysiology and orthopedics, Invuity’s interim CEO, Scott Flora, said in the release.

Invuity’s board of directors has recommended the acquisition to its shareholders, while the directors and executive officers have entered into and support this agreement with Stryker.

After the merger is completed, Imvuity’s shares will be delisted from the NASDAQ.

Stryker’s group president of neurotechnology, instruments and spine, said Invuity’s single-use lighted instrumentation and hybrid energy markets are some of the “best in class illumination and help make surgery faster.”

Invuity has multiple illuminator tools to help with hip replacement and mastectomy surgeries. The company has other surgery specific tools that will enhance Stryker’s portfolio.

  Life Science and Healthcare Investing in 2020 report cover

Coronavirus:
An Overview for Investors

 
COVID-19 continues to impact world markets. Get INN’s overview of coronavirus investing.
 

Unlike other surgical equipment, which makes use of tiny flash lights to help surgeons with the utmost precision during surgery, Invuity’s illuminated products have lights integrated on the products for the best view.

Stryker is a global medical device and technology company known for its advancements in joint replacement, trauma surgeries and medical equipment. Currently, the company’s main market drivers are orthopaedics, neurotechnology/spine and medical surgery equipment.

The acquisition agreement is still subject to customary terms, closing considerations and some regulatory approvals. As mentioned, Stryker will complete this transaction with its cash on hand.

Investors interested in Stryker can follow the company about this acquisition and others through the next couple months as the transaction should close by the end of 2019.

Don’t forget to follow @INN_LifeScience for real-time updates!

Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Medical Device Investing stock information

Get the latest information about companies associated with Medical Device Investing Delivered directly to your inbox.

Medical Device Investing

Select None
Select All

Leave a Reply